{"doi":"10.1053/j.jvca.2025.08.042","title":"Postoperative Cost-effectiveness of Prophylactic Amino Acid Therapy for Renal Protection: A Modeled Economic Evaluation","abstract":null,"journal":"Journal of Cardiothoracic and Vascular Anesthesia","year":2026,"id":641473,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1667906,"name":"Mussab Faggery","orcid":null,"position":1,"is_corresponding":false},{"id":1217203,"name":"Rosario Losiggio","orcid":"0009-0001-6181-7976","position":2,"is_corresponding":false},{"id":1217202,"name":"Domenico Pontillo","orcid":"0009-0007-1179-065X","position":3,"is_corresponding":false},{"id":1217200,"name":"Alessandro Pruna","orcid":"0009-0006-4588-2037","position":4,"is_corresponding":false},{"id":1208910,"name":"Giovanni Landoni","orcid":"0000-0002-8594-5980","position":5,"is_corresponding":false},{"id":419766,"name":"Rinaldo Bellomo","orcid":"0000-0002-1650-8939","position":6,"is_corresponding":false},{"id":802940,"name":"Alisa M. Higgins","orcid":"0000-0001-8295-7559","position":7,"is_corresponding":false},{"id":1475049,"name":"Alayna Carrandi","orcid":"0000-0002-5711-0417","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Postoperative Cost-effectiveness of Prophylactic Amino Acid Therapy for Renal Protection: A Modeled Economic Evaluation","abstract":"OBJECTIVE: To assess the cost-effectiveness of intravenous amino acids (AA) versus placebo in decreasing cardiac surgery-associated acute kidney injury (AKI) among adult patients after cardiac surgery. DESIGN: Data on resource use and outcomes were obtained from relevant studies reported in a recent meta-analysis. Cost-effectiveness analyses were conducted using a decision tree model to quantify the incremental costs and health outcomes of AA versus placebo. SETTING: Cost-effectiveness analyses were conducted separately for Australia, the United States, China, Italy, and the United Kingdom using local unit costs. PARTICIPANTS: Adult patients after cardiac surgery. INTERVENTIONS: Intravenous AA versus placebo. MEASUREMENTS AND MAIN RESULTS: The cost-effectiveness analyses expressed outcomes in terms of cost per instance of AKI averted with an in-hospital time horizon and from a healthcare payer perspective. The expected total healthcare cost after surgery in patients treated with AA ranged from $1,871 in China to $37,692 in the United States versus $2,055 in China to $40,213 in the United States for the placebo group, with a per patient cost saving ranging from $184 (95% confidence interval [CI], -$331 to -$32) in China to $2,521 (95% CI, -$3,770 to -$1,260) in the United States. AA also resulted in a 5.2% (95% CI, 5.1%-5.3%) absolute risk reduction in AKI. AA was dominant (cost-saving and cost-effective) across all jurisdictions. CONCLUSIONS: Compared with placebo, AA infusion decreases the occurrence of AKI and is cost-saving. Perioperative AA therapy is a rational approach to patient care that simultaneously protects renal function and decreases healthcare costs.","is_dataset_classified":null,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"41219099","pmcid":null,"openalex_id":"https://openalex.org/W4413452122","authors":[],"funders":[{"funder_name":"National Health and Medical Research Council","grant_id":"","title":null}],"total_grants":1,"fwci":2.8879,"citation_percentile":0.91648156,"influential_citations":0,"citation_trend":[{"year":2025,"count":1},{"year":2026,"count":3}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://doi.org/10.1053/j.jvca.2025.08.042","host_type":"journal"},{"url":"https://doi.org/10.1053/j.jvca.2025.08.042","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1053077025007189?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1053077025007189?httpAccept=text/plain","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/41219099","host_type":"repository"}],"fields_of_study":["Acute Kidney Injury Research","Trauma, Hemostasis, Coagulopathy, Resuscitation","Dialysis and Renal Disease Management"],"mesh_terms":["Amino Acids","Cost-Benefit Analysis","Cardiac Surgical Procedures","Humans","Postoperative Care","Postoperative Complications","Models, Economic","Acute Kidney Injury"],"keywords":["Medicine","Intensive care medicine","Heart surgery","kidney failure","Health Economics","Acute Renal Injury"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T18:13:22.643446Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}